Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This is according to the large randomized controlled START trial.
Hepatitis C increases risk of death among people on HIV treatment.
Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Researchers analyzed 10 biomarkers associated with biological aging among a group of HIV-positive and -negative Europeans.
Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Those with greater fibrosis before treating hep C see the greatest benefit.
This holds true regardless of how long they’ve had HIV or whether they’re on antiretrovirals.
However, while HbA1c and fasting glucose levels decline after a hep C cure, the clinical significance of such shifts remains unclear.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
Researchers believe this genetic mutation protected against the 14th century-bubonic plague.
Those who begin antiretrovirals with a higher CD4 count and CD4 to CD8 ratio are more likely to experience immune recovery.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
This finding suggests sex between men and the sharing of drug-sniffing equipment are possible routes of transmission.
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.